3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Carcinoma, Basal Cell
15
Neoplasms
5
Pancreatic Neoplasms
4
Stomach Neoplasms
3
Ovarian Neoplasms
3
Multiple Myeloma
3
Medulloblastoma
3
Colorectal Neoplasms
3
Basal Cell Nevus Syndrome
3
Urinary Bladder Neoplasms
2
Lymphoma
2
Hematologic Neoplasms
2
Breast Neoplasms
2
Brain Neoplasms
2
Adenocarcinoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Platinum-Resistant Fallopian Tube Carcinoma
1
Pancreatic Diseases
1
Odontogenic Cysts
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Unknown Primary
1
Neoplasms, Basal Cell
1
Neoplasms by Site
1
Interventions
Gemcitabine
9
Carboplatin
8
Paclitaxel
6
Capecitabine
4
Bevacizumab
4
pembrolizumab
3
Irinotecan
3
Erlotinib Hydrochloride
3
atezolizumab
2
Peripheral Blood Stem Cell Transplantation
2
Oxaliplatin
2
Filgrastim
2
Cisplatin
2
CP protocol
2
tislelizumab
1
tegafur-gimeracil-oteracil
1
spartalizumab
1
sintilimab
1
pertuzumab
1
pemigatinib
1
olaparib
1
ivosidenib
1
ipatasertib
1
etoposide phosphate
1
entrectinib
1
cobimetinib
1
belinostat
1
antineoplaston AS 2-1
1
antineoplaston A10
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Unknown Primary
×
HhAntag691
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts